Insights & Resources – COD Research

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised
Source: EMA Published on 2026-08-21
Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Date of authorisation: 19/06/2026, Revision: 1, Status: Authorised
Source: EMA Published on 2026-08-21
Human medicines European public assessment report (EPAR): Imaavy, nipocalimab, Date of authorisation: 28/11/2025, Revision: 1, Status: Authorised
Source: EMA Published on 2026-08-21
Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 7, Status: Authorised
Source: EMA Published on 2026-08-21
Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 2, Status: Authorised
Source: EMA Published on 2026-08-21
Orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate Treatment of Charcot-Marie-Tooth disease, 14/12/2015 Positive
Source: EMA Published on 2026-08-21

Read More